Skip to Main Content

Paper Details

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Oncotarget
38
2015
-, -PTC cells, BCL2, BRAF, BRAF(, BRAF(V600E, BRAF(V600E), BRAF(V600E)-PTC, BRAF(WT)-PTC cells, BRAFV600E, CDKN2A, MCL1, NT, NT cells, P16, PTC, PTC and NT cultures, PTC cells, V600E, blood endothelial cells, chromosome 1q, chromosome 9p, human, lymphatic endothelial cells, metastatic BRAF(V600E)-PTC cells, mice, mouse, mutant BRAF, non-metastatic BRAF(V600E)-PTC cells, papillary thyroid carcinoma, patient, patients, pericytes, short, tumor, tumors, vemurafenib
Author NameAffiliation
Paul Van HummelenCenter for Cancer Genome Discovery (CCGD), Dana Farber Cancer Institute, Harvard Medical School
Thomas J GiordanoUniversity of Michigan
Dora Dias-SantagataCenter for Integrated Diagnostics, Massachusetts General Hospital, Harvard Medical School
  • 1 - 3

Datasets